NTLA
Price
$12.18
Change
-$0.07 (-0.57%)
Updated
Feb 21, 04:59 PM (EDT)
Capitalization
1.24B
68 days until earnings call
PRME
Price
$2.96
Change
-$0.17 (-5.43%)
Updated
Feb 21, 04:59 PM (EDT)
Capitalization
388.24M
12 days until earnings call
Ad is loading...

NTLA vs PRME

Header iconNTLA vs PRME Comparison
Open Charts NTLA vs PRMEBanner chart's image
Intellia Therapeutics
Price$12.18
Change-$0.07 (-0.57%)
Volume$182.03K
Capitalization1.24B
Prime Medicine
Price$2.96
Change-$0.17 (-5.43%)
Volume$11.94K
Capitalization388.24M
NTLA vs PRME Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. PRME commentary
Feb 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and PRME is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 22, 2025
Stock price -- (NTLA: $12.25 vs. PRME: $3.13)
Brand notoriety: NTLA and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 153% vs. PRME: 118%
Market capitalization -- NTLA: $1.24B vs. PRME: $388.24M
NTLA [@Biotechnology] is valued at $1.24B. PRME’s [@Biotechnology] market capitalization is $388.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $369.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 5 bullish TA indicator(s).

  • NTLA’s TA Score: 5 bullish, 4 bearish.
  • PRME’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both NTLA and PRME are a good buy in the short-term.

Price Growth

NTLA (@Biotechnology) experienced а +27.07% price change this week, while PRME (@Biotechnology) price change was +20.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.57%. For the same industry, the average monthly price growth was +3.87%, and the average quarterly price growth was +3.11%.

Reported Earning Dates

NTLA is expected to report earnings on May 01, 2025.

PRME is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (+4.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.24B) has a higher market cap than PRME($388M). PRME YTD gains are higher at: 7.192 vs. NTLA (5.060). PRME has higher annual earnings (EBITDA): -207.13M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. PRME (176M). PRME has less debt than NTLA: PRME (41.2M) vs NTLA (102M). NTLA has higher revenues than PRME: NTLA (43.1M) vs PRME (800K).
NTLAPRMENTLA / PRME
Capitalization1.24B388M320%
EBITDA-527.52M-207.13M255%
Gain YTD5.0607.19270%
P/E RatioN/AN/A-
Revenue43.1M800K5,388%
Total Cash658M176M374%
Total Debt102M41.2M248%
FUNDAMENTALS RATINGS
NTLA vs PRME: Fundamental Ratings
NTLA
PRME
OUTLOOK RATING
1..100
159
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
6159
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for PRME (72) in the null industry. This means that NTLA’s stock grew somewhat faster than PRME’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that NTLA’s stock grew similarly to PRME’s over the last 12 months.

NTLA's SMR Rating (96) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that NTLA’s stock grew similarly to PRME’s over the last 12 months.

PRME's Price Growth Rating (59) in the null industry is in the same range as NTLA (61) in the Biotechnology industry. This means that PRME’s stock grew similarly to NTLA’s over the last 12 months.

PRME's P/E Growth Rating (100) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAPRME
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 11 days ago
86%
Bearish Trend 11 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NVSOX13.47N/A
N/A
Allspring Disciplined Small Cap Adm
SSDAX32.72N/A
N/A
DWS Small Cap Growth A
GIXIX9.28N/A
N/A
Nationwide International Index R6
AGWUX62.30N/A
N/A
American Century Growth R5
TIOVX15.64N/A
N/A
Nuveen International Opps W

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-0.24%
VCYT - NTLA
69%
Closely correlated
-2.52%
BEAM - NTLA
61%
Loosely correlated
-2.79%
CRSP - NTLA
61%
Loosely correlated
-4.88%
PRME - NTLA
57%
Loosely correlated
-4.72%
ALLO - NTLA
56%
Loosely correlated
-13.27%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-4.72%
CRSP - PRME
64%
Loosely correlated
-4.88%
NTLA - PRME
58%
Loosely correlated
-0.24%
BEAM - PRME
57%
Loosely correlated
-2.79%
RXRX - PRME
54%
Loosely correlated
-4.78%
ABCL - PRME
53%
Loosely correlated
-9.51%
More